Press Release

Biochip Market to Grow with a CAGR of 14.09% through 2028

Increase in number of biochip applications and high adoption of personalized medication is expected to drive the Global Biochip Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Biochip Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Biochip Market stood at USD 14.96 billion in 2022 and is anticipated to grow with a CAGR of 14.09% in the forecast period, 2024-2028. The increasing utilization of biochips in proteomics, genomics, and drug discovery, along with the growth in personalized medicine, is expected to drive market expansion.

Moreover, technological advancements and component miniaturization are anticipated to create favorable prospects for market players in the foreseeable future. Other factors contributing to market growth include the rise in the geriatric population, the increasing number of biochip applications, and the high adoption of personalized medications.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Biochip Market.”


The biochip segment is witnessing significant growth as emerging players mature in the field. This can be attributed to the increasing adoption of personalized medicines, rising drug development, and the advent of next-generation sequencing (NGS). The global market growth is expected to be driven by innovation in Lab-on-a-chip offerings and advancements in microfluidic-based devices for biomedical applications. Lab-on-a-chip devices are anticipated to provide rapid results during the initial diagnosis of infectious diseases, making them widely utilized in epidemiological studies.

Researchers have found that biochips offer rapidity comparable to antigen tests and accuracy similar to PCR testing. The combination of biochip technology with various applications is projected to propel the growth of the biochip market. For example, in March 2022, Nutcracker, a U.S.-based startup, secured USD 167 million in series C funding to enhance their biochip-based RNA manufacturing platform. This platform is expected to support the advancement of RNA-based therapeutics. The biochip and nanoparticle delivery technologies aid in establishing comprehensive isolated and automated manufacturing processes. Furthermore, the growing use of biochip applications, including drug development, has compelled several R&D institutions and teams to design cost-effective and efficient processes. In 2021, there were over 700 drugs in progress targeting approximately 8,000 rare diseases.

Biochips are utilized for pre-clinical testing of drugs. In May 2022, the Vienne University of Technology (TU Wien) developed a biochip-based technology to manufacture tissue beads of precise sizes. These tissue beads can be commercialized along with drugs through a thin channel. A patent application for this technology has been submitted. However, the high cost of manufacturing biochips may hinder industry growth. The majority of microfluidic devices are produced using ultraviolet lithography, an intricate and expensive technique that requires trained professionals with specialized instruments.


The advancement of nanotechnology has increased the capability and reduced the size of biochips, making them valuable for diagnostics, research, drug development, and toxicology studies. This has led to growing adoption of biochips in various applications such as genomics, proteomics, and personalized medicine. Existing manufacturers and new startups are prompted to develop and invest in new technologies for the market. For instance, Dutch startup Qurin Diagnostics offers novel biomedical diagnostics using biochips. Their nanotechnology-based platform is used for monitoring, diagnosing, and treating cancer and other medical conditions. Similarly, on March 14, 2022, U.S. startup Nutcracker Therapeutics raised USD 167 million for the advancement of its mRNA biochip-based manufacturing platform. In May 2021, TU Wien developed a biochip capable of producing tissue beads in desired sizes and supplying them with drugs or nutrients.

The comprehensive drug development pipeline is one of the major factors driving the growth of the biochip market. The need to reduce turnaround time and miniaturize biological and clinical tests for research and diagnosis has increased the demand for biochip and bio-array techniques. Rapid technical developments related to these techniques and a wide product portfolio further accelerate the growth of the biochips market. Biochips find applications in disease marker identification, accelerated drug development, genotyping, proteomics, and genomics research. The rise in spending on clinical research and resource allocation for genomic and proteomic research also influence the biochips market. Additionally, factors such as the growth in the aging population, improving healthcare infrastructure, and surge in healthcare expenditure contribute positively to the biochips market. Furthermore, new product launches present profitable opportunities for biochip market players in the forecast period of 2024 to 2028.

The high cost of manufacturing biochips creates barriers for new players to enter the market and produce a wide range of alternatives for end-users. Limited awareness among developing and under-developed regions about the utility of biochips is also a concerning factor for the global biochip market. Over the years, the quantity of biochip-based research conducted by research and academic institutes in developing countries has decreased. Moreover, the limited knowledge among emerging companies in the drug development and personalized medicine sector is projected to hinder global market growth.The Global Biochip Market is segmented into technology, type, application, end user, regional distribution, and company.

Based on technology, the global biochip market is categorized into microfluidics and microarray. In 2022, the microfluidics segment accounted for a significant revenue share due to the increasing demand for microfluidics-based POC-diagnostic devices like pregnancy tests and glucose monitoring kits. These devices are small, highly sensitive, accurate, cost-effective, and capable of detecting multiple analyses in one sample. Biochips provide a platform for automated drug discovery, DNA analysis, and biomolecular recognition, while replacing heavy equipment with integrated and miniaturized systems to automate repetitive laboratory tasks.

During the forecast period, the microarray technology segment is expected to witness rapid growth. This can be attributed to the extensive use of biochips in the drug development process for identifying therapeutic candidates. Microarray technologies offer significant time and labor savings compared to other techniques.


Based on region, North America segment is expected to grow during the forecast period. Based on regional analysis, the biochip market in North America accounted for the largest revenue share in 2022. This can be attributed to the increasing incidence of cardiac and chronic diseases, along with the accessibility of advanced healthcare systems in the region, particularly in the U.S. The high prevalence of diseases like diabetes and cancer further drives the demand for clinical and research diagnosis. The government is also launching various initiatives to promote precision medicine and increasing investments in cancer genomics research, which are expected to drive revenue growth in North America.

Meanwhile, the market in Asia Pacific is projected to experience a rapid growth rate during the forecast period, primarily due to the expanding pharma and biotech industry in countries like China and India. China is making significant investments in scientific research to accelerate the development of precision medicines and enhance new drug discoveries. Additionally, increased investments in genomics, proteomics, and next-generation sequencing research, combined with growing patient awareness regarding advancements in diagnostic technologies, are contributing to the growth of the market. The increasing healthcare expenditure in the region is expected to further support the revenue growth of the industry throughout the forecast period.


Major companies operating in Global Biochip Market are:

  • Abbott Laboratories Inc.
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Fluidigm Corporation
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • Illumina Inc.
  • Phalanx Biotech Group Inc.
  • BioMerieux SA
  • Qiagen NV


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The rising prevalence of chronic diseases like diabetes, blood pressure, and COPD supports the global market growth. The increased utilization of biochips in genomics, proteomics, and molecular diagnostics also has a positive impact. Benefits such as time and cost reduction, high throughput, and no heavy instrument requirement contribute to market growth. The demand for timesaving, high-quality devices in the healthcare industry, along with the preference for personalized medicines and NGS, drives market growth. Biochips are also used for early cancer detection and offer lucrative opportunities. The growing geriatric population, demand for biochips in drug development, and biomedical advancements in microfluidic-based devices and lab-on-a-chip technologies drive market growth.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Biochip Market Segmented By Technology (Microarray v/s Microfluidics), By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, In-vitro diagnostics, Others), By End User (Hospitals & Diagnostics Centres, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Others), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Biochip Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Biochip Market.


Mr. Ken Mathews         

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656                                                     

Email: [email protected]               


Relevant News